Shire sees 23% growth as it eyes $10bn in sales by 2020
This article was originally published in Scrip
Executive Summary
Shire CEO Flemming Ornskov called 2014 a "historic, transformational" year which saw "record progress", and sales climb by 23% to $5.8bn. And 2015 got off to a flying start: within the first few weeks Shire announced its largest acquisition to date and the first approval for a drug to treat binge-eating disorder, Vyvanse.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.